Claims for Patent: 12,083,182

Summary for Patent: 12,083,182

Title:	Controlled-release CNP agonists with increased NEP stability
Abstract:	The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.
Inventor(s):	Kennett Sprogøe, Harald Rau, Ulrich Hersel, Felix Cleemann
Assignee:	Ascendis Pharma Endocrinology Division AS
Application Number:	US17/538,971
Patent Claims:	1. A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with a CNP agonist, comprising the step of administering to the patient a therapeutically effective amount of a controlled-release CNP agonist comprising a CNP moiety (-D) comprising a ring moiety, wherein the ring moiety has the amino acid sequence of SEQ ID NO:96, provided the methionine at position 11 of SEQ ID NO:96 can be substituted with asparagine, the ring moiety being between two cysteine residues forming a disulfide bridge, and being conjugated to a polymer via a reversible prodrug linker cleavable in aqueous buffer at pH 7.4 and 37° C. in the absence of enzymes with a half-life of up to six months, wherein the polymer is water-soluble and a branched polymer of at least 10 kDa, wherein the controlled-release CNP agonist on cleavage of the reversible prodrug linker releases -D in its free form (D-H) and wherein the controlled-release CNP agonist has an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released D-H. 2. The method of claim 1, wherein the controlled-release CNP agonist has an at least 15-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding D-H. 3. The method of claim 1, wherein the controlled-release CNP agonist has an at least 25-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding D-H. 4. The method of claim 1, wherein the controlled-release CNP agonist releases the D-H under aqueous buffer at pH 7.4 and 37° C. with a release half-life of at least 6 hours. 5. The method of claim 1, wherein the controlled-release CNP agonist releases the D-H under aqueous buffer at pH 7.4 and 37° C. with a release half-life of at least 24 hours. 6. The method of claim 1, wherein the controlled-release CNP agonist releases the D-H under aqueous buffer at pH 7.4 and 37° C. with a release half-life of at least 48 hours. 7. The method of claim 1, wherein the controlled-release CNP agonist releases the D-H under aqueous buffer at pH 7.4 and 37° C. with a release half-life of at least 168 hours. 8. The method of claim 1, wherein the one or more diseases which can be treated with CNP is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasia, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata, homozygous achondroplasia, camptomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata, Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, Kniest syndrome, metatrophic dysplasia, spondyloepimetaphyseal dysplasia, neurofibromatosis, LEOPARD syndrome, Noonan syndrome, hereditary gingival fibromatosis, neurofibromatosis type 1, Legius syndrome, cardiofaciocutaneous syndrome, Costello syndrome, SHOX deficiency, idiopathic short stature, growth hormone deficiency, osteoarthritis, cleidocranial dysostosis, craniosynostosis, dactyly, brachydactyly, camptodactyly, polydactyly, syndactyly, dyssegmental dysplasia, enchondromatosis, fibrous dysplasia, hereditary multiple exostoses, hypophosphatemic rickets, Jaffe-Lichtenstein syndrome, Marfan syndrome, McCune-Albright syndrome, osteopetrosis and osteopoikilosis. 9. The method of claim 1, wherein the one or more diseases which can be treated with CNP is selected from the group consisting of Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, and Crouzonodermoskeletal syndrome. 10. The method of claim 1, wherein the disease is achondroplasia. 11. The method of claim 1, wherein the polymer is at least 30 kDa. 12. The method of claim 1, wherein the controlled-release CNP agonist is of formula (Ia): ZL2-L1-D)x (Ia), or a pharmaceutically acceptable salt thereof, wherein -D is the CNP moiety; -L1- is a reversible prodrug linker moiety; -L2- is a single chemical bond or spacer moiety; —Z is a water-soluble and branched polymer moiety of at least 10 kDa; and x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16. 13. The method of claim 12, wherein —Z is of formula (g): wherein the dashed line indicates attachment to -L2-; —Sg—, —Sg′— and —Sg″— are independently selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R′, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R2)—, —S(O)2N(R2)—, —S(O)N(R2)—, —S(O)2—, —S(O)—, —N(R2)S(O)2N(R2a)—, —S—, —N(R2)—, —OC(OR2) (R2a)—, —N(R2)C(O)N(R2a)—, and —OC(O)N(R2)—; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R′, which are the same or different; each —R′ is independently selected from the group consisting of halogen, —CN, oxo (═O), —COORS, —OR3, —C(O)R3, —C(O)N(R3R3a), —S(O)2N(R3R3a), —S(O)N(R3R3a), —S(O)2R3, —S(O)R3, —N(R3)S(O)2N(R3aR3b), —SR3, —N(R3R3a), —NO2, —OC(O)R3, —N(R3)C(O)R3a, —N(R3)S(O)2R3a, —N(R3)S(O)R3a, —N(R3)C(O)OR3a, —N(R3)C(O)N(R3aR3b), —OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each —R2, —R2a, R3, R3a and —R3b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and —Za and —Za′ are independently wherein the dashed line indicates attachment to the remainder of —Z; BPa is a branching point selected from the group consisting of —N<, —CR< and >C<; —R is selected from the group consisting of —H and C1-6 alkyl; a is 0 if BPa is —N< or —CR< and a is 1 if BPa is >C<; —Sa—, —Sa′—, —Sa″— and —Sa′″ are independently of each other a chemical bond or are selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R2)—, —S(O)2N(R2)—, —S(O)N(R2)—, —S(O)2—, —S(O)—, —N(R2)S(O)2N(R2a)—, —S—, —N(R2)—, —OC(OR2)(R2a)—, —N(R2)C(O)N(R2a)—, and —OC(O)N(R2)—; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more —R′, which are the same or different; each —R′ is independently selected from the group consisting of halogen, —CN, oxo (═O), —COORS, —OR3, —C(O)R3, —C(O)N(R3R3a), —S(O)2N(R3R3a), —S(O)N(R3R3a), —S(O)2R3, —S(O)R3, —N(R3)S(O)2N(R3aR3b), —SR3, —N(R3R3a), —NO2, —OC(O)R3, —N(R3)C(O)R3a, —N(R3)S(O)2R3a, —N(R3)S(O)R3a, —N(R3)C(O)O R3a, —N(R3)C(O)N(R3aR3b), —OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each —R2, —R2a, —R3, —R3a and —R3b is independently selected from the group consisting of —H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and —Pa′, —Pa″ and —Pa′″ are independently a polymeric moiety. 14. The method of claim 1, wherein the controlled release CNP agonist is administered as a pharmaceutical composition further comprising a tyrosine kinase inhibitor. 15. The method of claim 1, wherein the the controlled release CNP agonist is administered as pharmaceutical composition further comprising NVP-BGJ398.